Watch VYGR. Know when insiders buy.
One email the day a filing lands. Free.
VYGR
Voyager Therapeutics, Inc.
2.45
−0.23 −8.58%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
61
WATCH · shorts 61
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $151MP/E —DIV YIELD —FCF YIELD -80.43%REV TTM $34.5M −19.1%NET INCOME −$107.7MNET CASH —52W 2.45 – 5.33SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3.2M | −39.1% | — | −$26.4M | −$24.5M | — | -0.40 | −$25.8M | $0 | −$25.8M | Aug 6 |
| Q1 2026 · Mar 31 | $2.6M | −59.9% | — | −$30.3M | −$27.9M | — | -0.47 | −$33.4M | $14K | −$33.4M | Aug 6 |
| Q4 2025 · Dec 31derived | $15.3M | +144.3% | — | −$29.9M | −$27.4M | — | -0.47 | −$30.3M | $626K | −$30.9M | Mar 9 |
| Q3 2025 · Sep 30 | $13.4M | −45.7% | — | −$30.6M | −$27.9M | — | -0.47 | −$31M | $207K | −$31.3M | Nov 10 |
| Q2 2025 · Jun 30 | $5.2M | −82.4% | — | −$36.6M | −$33.4M | — | -0.57 | −$33.3M | $1.1M | −$34.4M | Aug 6 |
| Q1 2025 · Mar 31 | $6.5M | −66.8% | — | −$34.7M | −$31M | — | -0.53 | −$37.9M | $658K | −$38.6M | Aug 6 |
| Q4 2024 · Dec 31derived | $6.3M | −93.0% | — | −$38.3M | −$34.5M | −161.2% | -0.60 | −$14.5M | $155K | −$14.7M | Mar 9 |
| Q3 2024 · Sep 30 | $24.6M | +433.8% | — | −$13.8M | −$9M | — | -0.16 | −$28M | $258K | −$28.2M | Nov 10 |
| Q2 2024 · Jun 30 | $29.6M | — | — | −$15M | −$10.1M | — | -0.18 | −$31.6M | $967K | −$32.5M | Nov 10 |
| Q1 2024 · Mar 31 | $19.5M | — | — | −$16.2M | −$11.3M | — | -0.20 | $58.8M | $2.1M | $56.6M | Nov 10 |
| Q4 2023 · Dec 31derived | $90.1M | — | — | $54.1M | $56.4M | — | 1.19 | −$23.8M | $755K | −$24.5M | Mar 9 |
| Q3 2023 · Sep 30 | $4.6M | — | — | −$29.5M | −$25.9M | — | -0.59 | −$21.1M | $782K | −$21.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $40.4M | — | −$131.8M | −$119.7M | -296.5% | -2.04 | −$132.5M | $2.6M | −$135.1M | — | — |
| FY2024 · to Dec 31 | $80M | — | −$83.3M | −$65M | -81.3% | -1.13 | −$15.3M | $3.5M | −$18.8M | — | — |
| FY2023 · to Dec 31 | $250M | — | $122M | $132.3M | 52.9% | 2.97 | $77.9M | $3.3M | $74.7M | — | — |
| FY2022 · to Dec 31 | $40.9M | — | −$50.8M | −$46.4M | -113.4% | -1.21 | −$12.5M | $2.5M | −$15M | — | — |
| FY2021 · to Dec 31 | $37.4M | — | −$73.6M | −$71.2M | -190.3% | -1.89 | −$53.5M | $1.6M | −$55.1M | — | — |
| FY2020 · to Dec 31 | $171.1M | — | $27.4M | $36.7M | 21.5% | 0.98 | −$96.7M | $12.1M | −$108.8M | — | — |
Every number comes from Voyager Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.